ArticleAdvanced pharmaceutical bulletin2026
The Effect of Glycosylation on Biodistribution and Cytotoxicity of
Article in Advanced pharmaceutical bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Luteolin (Lu) and its glycosylated derivative, luteolin-7-O-glucoside (LuG), are the main bioactive flavonoids reported in the Methods: Lu and LuG were isolated from Results: LuG exhibited preferential accumulation in the liver (~28.7%) and significant cytotoxicity on HepG2 cells. Flow cytometry indicated non-apoptotic cell death and G1/S phase cell cycle arrest in HepG2 cells treated with LuG, whereas Lu showed less accumulation and cytotoxicity. Biodistribution data revealed lower accumulation in other organs, and LuG had negligible toxicity on non-hepatic cells (HUVEC, SW480). Overall biodistribution analysis revealed lower off-target accumulation, further supporting the hepatic selectivity of LuG. Conclusion: This study provides the first integrated evidence of the liver-targeted biodistribution and selective anticancer effects of LuG. These findings demonstrate LuG as a candidate therapeutic for hepatocellular carcinoma. These results emphasize the importance of pharmacological evaluation of flavonoid glycosides and support preclinical development of LuG as a targeted anticancer agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.